Captain Chesley "Sully" Sullenberger, the retired airline pilot who became a national hero after safely landing US Airways Flight 1549 on the Hudson River in January 2009, has revealed he has been diagnosed with Alzheimer's disease. He announced his diagnosis publicly at age 70, according to reporting by BBC News.
The widely praised emergency water landing saved the lives of all 155 passengers and crew aboard the aircraft after both engines were disabled by bird strikes shortly after takeoff from LaGuardia Airport in New York. Sully retired from US Airways in 2009 and has since worked as a safety consultant, author, and motivational speaker.
What the Left Is Saying
Progressive advocates and Democratic lawmakers have praised Sully for his transparency about his diagnosis. Representative Katie Porter of California said on social media that Sully's willingness to share his journey "takes tremendous courage" and could help reduce stigma around neurological conditions affecting older Americans.
Organizations focused on Alzheimer's awareness noted that public figures sharing diagnoses can accelerate research funding and support services. The Alzheimer's Association, in a statement attributed to Chief Program Officer Beth Kallmyer, said high-profile disclosures "help normalize conversations about cognitive health" and encourage earlier screening among the general population.
Some progressive health policy advocates pointed to Sully's announcement as a reminder of the broader need for dementia care infrastructure. Families USA Executive Director Frederick Isasi noted that with over 6 million Americans living with Alzheimer's, public awareness campaigns featuring respected figures "can be powerful tools for driving policy change."
What the Right Is Saying
Conservative commentators and Republican officials have largely framed Sully's announcement within narratives of personal responsibility and private healthcare decisions. Former Representative Lee Zeldin said in a statement that Sully has "served America with distinction" and deserves privacy as he navigates his diagnosis.
Several conservative health policy voices emphasized the importance of continued investment in Alzheimer's research through market-driven approaches rather than expanded government programs. American Enterprise Institute Health Policy Fellow Tara O'Neill noted that private-sector innovation "has driven remarkable advances" in understanding neurological diseases.
Senator Tommy Tuberville of Alabama, who has championed biomedical research funding, said on X that Sully's announcement underscores the need to maintain momentum toward treatments and cures. The Senator pointed to recent FDA approvals of Alzheimer's treatments as evidence that research investments are yielding results.
What the Numbers Show
According to the Alzheimer's Association's 2024 report, approximately 6.7 million Americans age 65 and older are currently living with Alzheimer's dementia. That number is projected to rise to nearly 12.7 million by 2050 without significant medical breakthroughs.
The National Institutes of Health allocated approximately $3.8 billion for Alzheimer's and related dementias research in fiscal year 2024, representing a substantial increase from roughly $631 million a decade earlier. Congressional appropriations have generally maintained bipartisan support for such funding.
A 2023 Gallup poll found that Americans rank Alzheimer's as the disease they fear most developing, cited by 41% of respondents—more than cancer (31%) or heart disease (8%). However, only 45% of adults reported having discussed cognitive decline with a healthcare provider.
Medicare spending on beneficiaries with Alzheimer's dementia exceeded $78 billion in 2023, accounting for a significant portion of the program's expenditures. Private long-term care costs average approximately $108,000 annually for nursing home care nationally.
The Bottom Line
Sully's announcement brings renewed attention to Alzheimer's disease at a time when scientific advances have generated cautious optimism about treatment options. His status as a widely respected public figure gives his disclosure unusual reach and potential impact on public awareness campaigns.
What happens next will likely involve continued advocacy work by Sully, who indicated in his statement that he plans to remain active in safety and health initiatives for as long as possible. Healthcare advocates across the political spectrum say they hope his visibility will encourage earlier screening and family conversations about cognitive health.
Congress is expected to continue debates about NIH funding levels and Medicare coverage questions related to new Alzheimer's treatments approved by the FDA. The balance between supporting research innovation and managing federal healthcare costs remains a key point of discussion in ongoing budget negotiations.